Pretreatment prognostic indices predictive of outcome in patients with clinically localized prostate cancer typically rely on risk-factors including: prostate-specific antigen (PSA), clinical T-stage, and biopsy Gleason score (GS) [1,2]. This evidence concerns the gene KLK3 and prostate cancer.